Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by OncoPharmPod and John Bossaer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by OncoPharmPod and John Bossaer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

EGFRm NSCLC Updates

13:41
 
Share
 

Manage episode 505726562 series 1848091
Content provided by OncoPharmPod and John Bossaer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by OncoPharmPod and John Bossaer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
The 2025 World Conference on Lung Cancer just concluded, and there are several notable updates concerning treatment of EGFR-mutated NSCLC. 1. The COMPEL study tries to find the value of continuing osimertinib (with the addition of chemotherapy) after progression on osimertinib. The results are, well, compelling! 2/3. We now have updates on the OS benefits of osimertinib + chemotherapy (FLAURA2) and amivantamab + lazertinib (MARIPOSA) compared to osimertinib monotherapy in initial treatment of metastatic disease. 4. NEOADAURA tries to determine if neoadjuvant osimertinib has value, but longer follow-up will be needed to assess this practice.
  continue reading

394 episodes

Artwork

EGFRm NSCLC Updates

OncoPharm

52 subscribers

published

iconShare
 
Manage episode 505726562 series 1848091
Content provided by OncoPharmPod and John Bossaer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by OncoPharmPod and John Bossaer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
The 2025 World Conference on Lung Cancer just concluded, and there are several notable updates concerning treatment of EGFR-mutated NSCLC. 1. The COMPEL study tries to find the value of continuing osimertinib (with the addition of chemotherapy) after progression on osimertinib. The results are, well, compelling! 2/3. We now have updates on the OS benefits of osimertinib + chemotherapy (FLAURA2) and amivantamab + lazertinib (MARIPOSA) compared to osimertinib monotherapy in initial treatment of metastatic disease. 4. NEOADAURA tries to determine if neoadjuvant osimertinib has value, but longer follow-up will be needed to assess this practice.
  continue reading

394 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play